Value of vanin-1 assessment in adult patients with primary immune thrombocytopenia

References

• George JN. Definition, diagnosis and treatment of immune thrombocytopenic purpura. Haematologica 2009;94:759–762
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–186
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–2393
   PubMed Web of Science ®Google Scholar
• Cooper N, Bussel J. The pathogenesis of immune thrombocytopenic purpura. Brit J Haematol 2006;133:364–374
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99(1):4–13
   PubMed Web of Science ®Google Scholar
• Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist 2009;14(1):12–21
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346(13):995–1008
   PubMed Web of Science ®Google Scholar
• Olsson B, Andersson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9(9):1123–1124
   PubMed Web of Science ®Google Scholar
• Kurien BT, Hensley K, Bachmann M, Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 2006;41(4):549–556
   PubMed Web of Science ®Google Scholar
• Berruyer C, Pouyet L, Millet V, Martin FM, LeGoffic A, Canonici A, Garcia S, Bagnis C, Naquet P, Galland F. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med 2006;203(13):2817–2827
   PubMed Web of Science ®Google Scholar
• Aurrand-Lions M, Galland F, Bazin H, Zakharyev VM, Imhof BA, Naquet P. Vanin-1, a novel GPI-linked perivascular molecule involved in thymus homing. Immunity 1996;5:391–405
   PubMed Web of Science ®Google Scholar
• Pitari G, Malergue F, Martin F, Philippe JM, Massucci MT, Chabret C, Maras B, Duprè S, Naquet P, Galland F. Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Lett 2000;483:149–154
   PubMed Web of Science ®Google Scholar
• Berruyer C, Martin FM, Castellano R, Macone A, Malergue F, Garrido-Urbani S, Millet V, Imbert J, Duprè S, Pitari G, Naquet P, Galland F. Vanin-1−/− mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Mol Cell Biol 2004;24:7214–7224
   PubMed Web of Science ®Google Scholar
• Szanto A, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology 2008;213(9):789–803
   PubMed Web of Science ®Google Scholar
• Zhang B, Lo C, Shen L, Sood R, Jones C, Cusmano-Ozog K, Park-Snyder S, Wong W, Jeng M, Cowan T, et al. The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood 2011;117:4569–4579
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190–4207
   PubMed Web of Science ®Google Scholar
• Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. Current Protocols in Molecular Biology: John Wiley and Sons, Inc., New York, USA. 1995; (supplement 29): 9.7.1--9.7.2
   Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254
   PubMed Web of Science ®Google Scholar
• Kelton JG, Powers PJ, Carter CJ. A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. Blood 1982;60:1050–1053
   PubMed Web of Science ®Google Scholar
• Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999;104:442–447
   PubMed Web of Science ®Google Scholar
• McMillan R. The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura. Curr Hematol Rep 2005;4:160–165
   PubMedGoogle Scholar
• Kurien BT, Hensley K, Bachmann M, Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 2006;41(4):549–556
   PubMed Web of Science ®Google Scholar
• Iuchi Y, Kibe N, Tsunoda S, Suzuki S, Mikami T, Okada F, Uchida K, Fujii J. Implication of oxidative stress as a cause of autoimmune hemolytic anemia in NZB mice. Free Radic Biol Med 2010;48(7):935–944
   PubMed Web of Science ®Google Scholar
• Griffiths HR. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmun Rev 2008;7(7):544–549
   PubMed Web of Science ®Google Scholar
• Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008;7(7):567–573
   PubMed Web of Science ®Google Scholar
• Polat G, Tamer L, Tanriverdi K, Gürkan E, Baslamisli F, Atik U. Levels of malondialdehyde, glutathione and ascorbic acid in idiopathic thrombocytopaenic purpura. East Afr Med J 2002;79(8):446–449
   PubMedGoogle Scholar
• Suvajdzić N, Stanković B, Artiko V, Cvejić T, Bulat V, Bakrac M, Colović M, Obradović V, Atkinson HD. Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. Platelets 2006;7(4):227–230
   Google Scholar
• Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, Teramura M, Koda K, Nomura S, Sugihara S, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005; 81(2):162–168
   PubMed Web of Science ®Google Scholar
• Veneri D, Franchini M, Gottardi M, D'Adda M, Ambrosetti A, Krampera M, Zanetti F, Pizzolo G. Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2002;87(11):1177–1179
   PubMed Web of Science ®Google Scholar
• Izzotti A, Durando P, Ansaldi F, Gianiorio F, Pulliero A. Interaction between Helicobacter pylori, diet, and genetic polymorphisms as related to non-cancer diseases. Mutat Res 2009;667(1):142–157
   PubMed Web of Science ®Google Scholar
• Huang H, Dong X, Kang MX, Xu B, Chen Y, Zhang B, Chen J, Xie QP, Wu YL. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol 2010;105(7):1661–1669
   PubMed Web of Science ®Google Scholar
• Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52:711–760
   PubMed Web of Science ®Google Scholar